Drug Information

Drug General Information
Drug ID
D03CPM
Former ID
DIB001555
Drug Name
SLV-334
Indication Brain injury [ICD10:S09.90] Phase 2 [531869]
Company
Solvay SA
Target and Pathway
Target(s) Neutral endopeptidase Target Info Modulator
Endothelin converting enzyme Target Info Modulator
KEGG Pathway Renin-angiotensin system
Hematopoietic cell lineage
Protein digestion and absorption
Alzheimer's disease
NetPath Pathway EGFR1 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
Reactome Metabolism of Angiotensinogen to Angiotensins
WikiPathways Metabolism of Angiotensinogen to Angiotensins
Primary Focal Segmental Glomerulosclerosis FSGS
Alzheimers Disease
References
Ref 531869The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.